BC006 / Adagene, Dragon Boat Biopharmaceutical - LARVOL DELTA

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=96 | Not yet recruiting | Sponsor: Dragonboat Biopharmaceutical Company Limited

New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Guilin Sanjin: The new indication of BC006 monoclonal antibody injection of the holding subsidiary has been approved for drug clinical trials [Google translation] (Sina Corp) - "People's Finance...that Guilin Sanjin...announced on the evening of May 5 that recently, the company's controlling subsidiary Baochuan Biomedicine Technology received the clinical trial approval certificate for BC006 monoclonal antibody injection approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of the drug for the indication of idiopathic pulmonary fibrosis."

New trial • Idiopathic Pulmonary Fibrosis